JUN 05, 2018 8:00 AM PDT

Early Breast Cancer Patients Do Not Gain Response Advantage with Chemotherapy

WRITTEN BY: Mauri Brueggeman

In light of LabRoots’ theme this month of precision medicine, the most recent news release from the National Cancer Institute is groundbreaking.   Findings from a current clinical trial started in 2006, called TAILORx, indicate that a good portion of women with early hormone receptor (HR) positive, HER2-negative, axillary node negative breast cancer do not gain better cancer reduction rates with chemotherapy and hormone therapy combined compared to hormone therapy alone after surgical remove of tumor.  In fact, according to trial results, 70% of women with this type of common early breast cancer showed no advantage from chemotherapy treatment.

Breast cancer is one of the most common cancers in women across the globe.  In the United States, the American Cancer Society estimates that there will be over 266,000 new cases of breast cancer in 2018 alone.  While death rates have dropped over the past few decades, death rates in women under 50 years of age have remained steady. 

TAILORx is a long-term phase III clinical trial to examine whether hormone therapy alone is sufficient for treatment of this specific breast cancer type as compared to the chemotherapy/hormone therapy combination traditionally used.  To identify appropriate trial candidates, the researchers used a 21 gene assessment test to assign patients into groups based on breast cancer biomarkers, staging of disease, and recurrence risk.  This is a worldwide trial with groups and sites collaborating in the United States, Australia, Canada, Ireland, New Zealand, and Peru.  In total, over 10,200 women having this common but specific HR-positive, HER2-negative, axillary node negative breast cancer across the world were able to participate.

One of the key outcomes of this study will be the ability of providers to personalize their treatment recommendations to patients in the intermediate recurrence risk category.  Historically, oncologists have been able to guide therapeutic plans for women determined to be at high risk or low risk of cancer recurrence; the findings demonstrate that for most patients in this intermediate recurrence risk category, there is no benefit from receiving chemotherapy and hormone therapy.  Chemotherapy is very challenging because of the multitude of side effects and in some cases, the whole person is debilitated during treatment.  In terms of preserving quality of life and potential late-stage effects of chemotherapy including treatment related cancers later in life, having this new evidence will help significant numbers of patients in the short term and long term.  These findings also affect healthcare financial responsibilities for both the patient and the complex system in general.

Sources: National Cancer Institute https://www.cancer.gov/news-events/press-releases/2018/tailorx-breast-cancer-chemotherapy?cid=eb_govdel, American Cancer Society https://www.cancer.org/cancer/breast-cancer.html, ClinicalTrials.Gov https://clinicaltrials.gov/ct2/show/NCT00310180?term=TAILORx&rank=2,  

About the Author
  • Mauri S. Brueggeman is a Medical Laboratory Scientist and Educator with a background in Cytogenetics and a Masters in Education from the University of Minnesota. She has worked in the clinical laboratory, taught at the University of Minnesota, and been in post secondary healthcare education administration. She is passionate about advances and leadership in science, medicine, and education.
You May Also Like
SEP 29, 2020
Cancer
Gut microbiome influences oral therapy for prostate cancer treatment
SEP 29, 2020
Gut microbiome influences oral therapy for prostate cancer treatment
Research from a team of scientists at Lawson Health Research Institute and Western University suggests that bacteria in ...
OCT 05, 2020
Cancer
Does Having an Appendectomy Increase Your Risk for Cancer?
OCT 05, 2020
Does Having an Appendectomy Increase Your Risk for Cancer?
Cancer research is more than just the study of diagnostics and novel therapies. Researchers also investigate the causes ...
OCT 09, 2020
Genetics & Genomics
Using CRISPR to Destroy Cancer Cells
OCT 09, 2020
Using CRISPR to Destroy Cancer Cells
Researchers have developed a way to selectively target certain cancer cells with CRISPR.
OCT 12, 2020
Drug Discovery & Development
Researchers Solve Key Problem for Cancer Immunotherapy
OCT 12, 2020
Researchers Solve Key Problem for Cancer Immunotherapy
Cancer immunotherapies are becoming increasingly promising as a standard-of-care treatment. However, despite their promi ...
OCT 15, 2020
Cancer
How is mole growth really associated to skin cancer?
OCT 15, 2020
How is mole growth really associated to skin cancer?
New research published in the journal eLife questions the way we think about skin cancer. Focused on mole growth, the st ...
NOV 23, 2020
Cancer
Where are the geographic hotspots of high mortality rates for women with colorectal cancer?
NOV 23, 2020
Where are the geographic hotspots of high mortality rates for women with colorectal cancer?
A study published in Clinical and Translational Gastroenterology highlights the risk disparities in death rates fro ...
Loading Comments...